2002-44-0

2002-44-0 structure

Name: Pro-Leu-Gly-NH2
Chemical Name: (2S)-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide
CAS Number: 2002-44-0
Molecular Formula: C₁₃H₂₄N₄O₃
Molecular Weight: 284.35500
Catalog: Signaling Pathways GPCR/G Protein Dopamine Receptor
Create Date: 2018-12-16 16:11:41
Modify Date: 2024-01-02 12:47:04
MIF-1 (Melanostatin), an endogenous brain peptide, is a potent dopamine receptor allosteric modulator. MIF-1 inhibits melanin formation. MIF-1 blocks the effects of opioid receptor activation to modulate the analgesic effects of morphine and stress-induced analgesia (SIA). MIF-1 accesses from the blood to the CNS by directly crossing the blood-brain barrier (BBB)[1][2][3].

Name	(2S)-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide
Synonyms	Oxytocin C-terminal tripeptide Melanocyte stimulating hormone release inhibiting factor MSH-release inhibiting factor I MIF-I Melanostatin Oxytocin fragment 7-9 L-Prolyl-L-leucylglycinamide MFCD00037866 MELANOSTATIN EINECS 217-902-7 Pro-Leu-Gly-NH2 L-Prolyl-L-leucylglycylamide melanocyte-stimulating hormone release-inhibiting factor-1 MIF-I Prolylleucylglycine amide 7-9-Oxytocin MIF-1

Description	MIF-1 (Melanostatin), an endogenous brain peptide, is a potent dopamine receptor allosteric modulator. MIF-1 inhibits melanin formation. MIF-1 blocks the effects of opioid receptor activation to modulate the analgesic effects of morphine and stress-induced analgesia (SIA). MIF-1 accesses from the blood to the CNS by directly crossing the blood-brain barrier (BBB)[1][2][3].
Related Catalog	Signaling Pathways >> GPCR/G Protein >> Dopamine Receptor Signaling Pathways >> Neuronal Signaling >> Dopamine Receptor Research Areas >> Neurological Disease
In Vitro	MIF-1 (Melanostatin, 1 μM) provokes a reversible hyperpolarization and a suppression of spontaneous action potentials[2].
In Vivo	MIF-1 (Melanostatin, 1 mg/kg; i.p.; once, for 1 hour; male Wistar rats) modulates the analgesic effects of morphine and stress-induced analgesia (SIA)[1]. MIF-1 (Melanostatin, 1 mg/kg; i.p.; daily, for 8 weeks; Sprague-Dawley rats) attenuates spiroperidol-induced impairment of development of striatal dopamine D2 receptors in rats[3]. Animal Model: Male Wistar rats[1] Dosage: 1 mg/kg Administration: Intraperitoneal injection; once, for 1 hour Result: Decreased the analgesic effect of morphine. Increased the pain threshold for at least 1 h. Animal Model: Sprague-Dawley rats[3] Dosage: 1 mg/kg Administration: Intraperitoneal injection; daily, for 8 weeks Result: Attenuated the ontogenic impairment of striatal D2 receptors that was produced by spiroperidol (HY-B1371) treatment.
References	[1]. Bocheva A, et, al. Antiopioid properties of the TYR-MIF-1 family. Methods Find Exp Clin Pharmacol. 2004 Nov;26(9):673-7. [2]. Valentijn JA, et, al. Melanostatin (NPY) inhibited electrical activity in frog melanotrophs through modulation of K+, Na+ and Ca2+ currents. J Physiol. 1994 Mar 1;475(2):185-95. [3]. Saleh MI, et, al. MIF-1 attenuates spiroperidol alteration of striatal dopamine D2 receptor ontogeny. Peptides. 1989 Jan-Feb;10(1):35-9.

Density	1.147g/cm3
Boiling Point	626.2ºC at 760mmHg
Molecular Formula	C₁₃H₂₄N₄O₃
Molecular Weight	284.35500
Flash Point	332.5ºC
Exact Mass	284.18500
PSA	113.32000
LogP	0.68170
Vapour Pressure	1.34E-15mmHg at 25°C
Index of Refraction	1.51

Precursor 0
DownStream 2
16747-86-7 21688-11-9

2002-44-0	14485-80-4
21688-04-0	77133-61-0
41089-31-0	1000375-45-0
1000375-46-1	14317-68-1
24346-32-5	179899-85-5